Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil

David Martin¹, Paula M. Luz², Jordan E. Lake³, Jesse L. Clark³, Dayse P. Campos², Valdilea G. Veloso², Ronaldo I. Moreira², Sandra W. Cardoso², Jeffrey D. Klausner³ and Beatriz Grinsztejn²

¹Corresponding author: David Martin, 2032 McAllister St. Apt #3, San Francisco, CA 94118, USA. Tel: 917-941-7220. (dmartin@post.harvard.edu)

Abstract

Introduction: Pharmacy adherence measures such as pharmacy dispensing ratios (PDRs) have previously been shown to be predictive of virologic outcomes. We aimed to determine the optimal interval of PDR assessment for predicting virologic failure for HIV-infected patients on antiretroviral therapy (ART).

Methods: Using national Brazilian ART pharmacy refill data, we examined PDRs for patients ≥18 years of age with at least one HIV RNA level ≥180 days after ART initiation on or after 1 January 2011. Patients with a documented ART change ≤270 days prior to viral load test date were excluded. Logistic regression models were used to describe associations between virologic failure, defined as an HIV RNA level ≥400 copies/ml and PDRs, defined as the number of days index drug dispensed (non-nucleoside reverse-transcriptase inhibitor or protease inhibitor) per 180- and 90-day, interval preceding viral load testing, adjusting for sex, age, race, time since ART initiation and index drug. Backward elimination of insignificant variables was performed after adjusting for PDR. A predictive probability of virologic failure was calculated using the corresponding odds ratios for the PDR and any other significant variables. The diagnostic performance of the PDR interval was assessed by calculating the area under the receiver operating characteristic curve (AUROC) for the predictive probability with respect to virologic failure.

Results and Discussion: A total of 1,025 patients were included (68% were male, median age 40 years, median time on ART 3.4 years). The PDR was found to be significantly associated with virologic failure for all of the PDR intervals (p < 0.001). There was an increased risk of virologic failure for all PDRs <0.95. The 90–180 days interval had a AUROC of 0.842, compared to 0.841 and 0.829 for the 0–180 days and 0–90 days intervals, respectively. The PDR performed well as a predictive tool to identify patients in virologic failure with the 90–180-days interval prior to viral load testing being marginally more predictive.

Conclusions: The validation and use of the pharmacy dispensing ratio using public pharmacy refill data could aid in early identification of patients with poor adherence and prevent development of treatment failure and drug resistance in Brazil.

Keywords: adherence; antiretroviral therapy; pharmacy refill; cohort studies; Brazil; viral load
to predict current virologic outcomes; however, additional studies are needed to define the best parameters of pharmacy measures that are most predictive of future clinical and virologic outcomes, and best suited for use in clinical practice [10]. This study assessed the validity of using pharmacy dispensing ratios (PDRs) for predicting the likelihood of virologic failure for patients on ART, as well as determine the most predictive assessment interval for PDRs within our clinical cohort.

Methods
Study population
We conducted a cross-sectional study using data obtained from the longitudinal, clinical database of HIV-infected patients receiving care at the Instituto de Pesquisa Clínica Evandro Chagas (IPEC) in Rio de Janeiro, Brazil. IPEC has been providing care to HIV-infected patients since 1986. The clinical database was established in 1998 and has since been updated regularly using outpatient and inpatient medical records, and laboratory results. Pharmacy prescription pickup data were obtained from the national Brazilian ART pharmacy control system. That database contains information regarding drug regimen, number of days' supply of medication dispensed, regimen changes and justification for drug regimen changes for all patients enrolled in the National HIV/AIDS Programme.

Patients greater than or equal to 18 years of age with at least one HIV RNA level occurring from 1 January 2011 through 31 December 2011 greater than or equal to 180 days after ART initiation to allow time for virologic response to treatment were included in the analysis. Patients with a documented regimen change less than or equal to 270 days prior to viral load test date were excluded to ensure patients were on a stable regimen at time of viral load testing and to allow for virologic response to treatment changes.

Variables of interest
The first HIV RNA viral load test occurring greater than or equal 180 days after ART initiation occurring from 1 January 2011 through 31 December 2011 was analyzed for all patients. The outcome of interest was virologic failure, defined as ≥4000 copies/mL, to account for less sensitive virus detection thresholds of older testing platforms.

The PDR was calculated based on the number of days' supply of index drug dispensed per 180- and 90-day intervals preceding the viral load test date. A total of three assessment intervals were included; 0–180 days, 90–180 days and 0–90 days. Periods shorter than 90 days were not considered given that patients are generally required to pick up ARVs on a monthly basis. The index drug was defined as the non-backbone ARV included in the drug regimen, consisting of either a non-nucleoside reverse-transcriptase inhibitor (NNRTI) or protease inhibitor (PI). The decision to include only NNRTI- or PI-based regimens was based on prior data showing 90% of patients in treatment in 2011 were either on an NNRTI or PI based regimen [13]. No distinction was made between patients on first- or second-line regimens. The date of the last drug prescription dispensed within the assessment interval prior to the viral load test date was used to calculate the number of days left within the interval. If the number of days left within the interval was less than the days' supply of the prescription, only the supply intended to be used within the interval was included in the calculation of the PDR to avoid overestimation of the PDR. The date of the first prescription dispensed prior to the start of the assessment interval was used to determine if any of the supply of drug dispensed prior to the interval was to be included in the calculation of the PDR to avoid underestimation of the PDR. For example, if a patient filled a 30-day prescription 5 days prior to the end of the interval, only the 5-day supply of drug intended to be used during the interval would be included in the calculation of the PDR. This method only accounts for overestimation based on the last prescription filled, therefore patients could theoretically be in possession of a greater supply of drug than the number of days within the period.

Statistical methods
Adjusted logistic regression models were used to describe the association between virologic failure and PDR for each of the 180- and 90-day assessment intervals. The PDR was treated as a categorical variable according to the following thresholds, >0.95 or ≤0.95, which were based on prior studies citing increase likelihood of virologic failure in patients with ≤95% adherence [1,2]. Additional variables that were assessed as possible predictors of virologic failure included sex, age, race, time since ART initiation and index drug. Selection of variables was limited to information which was readily available in the IPEC clinical database. Logistic regression models were used to test the associations between individual variables and virologic failure. All variables were included in the initial model and, assuming a significance level of p < 0.05, backward elimination of insignificant variables was performed after adjusting for PDR. The corresponding odds ratios (OR) for PDR and any additional variables found to be significant were used to calculate a predictive probability of virologic failure. The diagnostic performance of each PDR interval was assessed by calculating the area under the receiver operating characteristic curve (AUROC) for the predictive probability with respect to virologic failure. An optimal cut-point for the predictive probability was determined based on maximizing the sensitivity and specificity for predicting the likelihood of virologic failure. The cut-point therefore represents the predicted probability threshold above which a patient would be considered to be in virologic failure. The bootstrap method was then used to calculate the sensitivity and specificity and corresponding 95% confidence intervals of the predictive probability cut-point for each of the PDR intervals.

Ethical approval
This study was approved by the ethics committee of the Evandro Chagas Clinical Research Institute of the Oswaldo Cruz Foundation (CAAE 0032.0.009.000-10). Written informed consent was obtained from all patients.
informed consent for enrolment in the cohort was obtained from all patients. Retrospective analysis of previously collected data delinked from personal identifying information was considered exempt by the Columbia and University of California Los Angeles IRBs.

Results
Characteristics of the study population
A total of 1,025 patients were included in the analysis of which 68% were male with a median age [interquartile range (IQR)] of 40 years [33, 47] and median time since ART initiation of 3.4 years [1.8, 6.0] of which 57% were on an NNRTI. Table 1 provides an overview of the demographic and clinical characteristics of the study population. Overall, 10.6% of patients were found to be in virologic failure. The median time since ART initiation in years [IQR] for patients found to be in virologic failure was 4.1 [2.3, 7.0] compared to 3.4 [1.8, 5.8] for patients not in virologic failure.

Less than 33% of patients had a PDR >0.95 (Table 2). The median PDR was similar between the three interval categories. A small number of patients had a PDR>1.0. Table 2 provides a description of the PDR variable by assessment interval.

Predictors of virologic failure
The PDR was found to be significantly associated with virologic failure for all of the PDR intervals (Table 3). There was an increased risk of virologic failure for all PDRs <0.95. Of the additional variables tested, only race and index drug were significantly associated with virologic failure after adjusting for PDR. Sex, age and time since ART initiation were not found to be significantly associated with virologic failure. PI-based regimens were significantly associated with an increased risk of virologic failure when compared to an NNRTI-based regimen across all PDR intervals. Patients on lopinavir/ritonavir had a more than two-fold increase risk of virologic failure compared to those on atazanavir. Table 3 displays the results of the adjusted logistic regression models describing the association between PDR and virologic failure.

All of the PDR assessment intervals were found to have statistically significant AUROC. The 90–180 days interval was marginally superior at predicting virologic failure. Table 4 displays the diagnostic performance of the predictive probability and associated sensitivities and specificities for the selected predictive probability cut-points.

Discussion
In our observational clinical cohort, the PDR performed well as a predictive tool to identify patients in virologic failure. Our results are consistent with prior studies which demonstrate that the PDR can be used as a predictor of virologic failure and that upstream measures of adherence (>90 days prior to test date) are better predictors of virologic failure than more recent measures [10,14]. The predictive value of PDRs based on 90-day versus 180-day intervals was found to be similar with the most predictive interval being the 90-day period occurring 90–180 days prior to viral load testing.

Table 1. Overall patient demographic and clinical characteristics

| Characteristics | n = 1025 |
|-----------------|---------|
| **Sex** | |
| Male: n (%) | 699 (68) |
| Female: n (%) | 326 (32) |
| **Race** | |
| White: n (%) | 537 (52) |
| Non-White: n (%) | 488 (48) |
| **Age (yrs): median (IQR)** | 40 (33, 47) |
| **Time since Initiation of ART (yrs): median (IQR)** | 3.4 (1.8, 6.0) |
| **Regimen containing** | |
| Efavirenz | 586 (57) |
| Atazanavir | 200 (20) |
| Lopinavir/Ritonavir | 239 (23) |
| **Virologic Failure: n (%)** | 109 (10.6) |

Table 2. Characteristics of Pharmacy Dispensing Ratios (PDRs) by assessment interval

| Interval | Median [IQR] | PDR ≤0.95 (%) | PDR >0.95 (%) |
|----------|--------------|---------------|---------------|
| 0–180 Days | 0.75 [0.62, 0.99] | 71% | 29% |
| 90–180 Days | 0.75 [0.58, 1.01] | 74% | 26% |
| 0–90 Days | 0.73 [0.58, 0.99] | 67% | 33% |

IQR: interquartile range

Table 3. Factors associated with virologic failure (≥400 Copies/mL)

| Significant Variables | 0–180 Days | 90–180 Days | 0–90 Days |
|-----------------------|------------|-------------|-----------|
| **PDR >0.95 (reference)** | - | - | - |
| **PDR ≤0.95** | 7.03 <0.001 | 6.00 <0.001 | 5.14 <0.001 |
| White (reference) | - | - | - |
| Non-White | 1.79 0.010 | 1.76 0.014 | 1.66 0.023 |
| **Efavirenz** (reference) | - | - | - |
| Lopinavir/Ritonavir | 12.33 <0.001 | 13.41 <0.001 | 12.67 <0.001 |
| Atazanavir | 5.05 <0.001 | 5.27 <0.001 | 5.12 <0.001 |

PDR: pharmacy dispensing ratio; OR, odds ratio
We acknowledge that the sensitivities and specificities obtained are not sufficient to replace the need for viral load monitoring. However, our results demonstrate the possibility of developing a cost-effective predictive tool that could be used at the national, regional or district level by public health authorities to identify patients at highest risk of virologic failure, in settings where the cost of more expensive strategies such as pill counts and biological markers are prohibitive. Sex, age and time since ART initiation were not significantly associated with virologic failure after adjusting for PDR. Non-White race was found to be associated with an increased risk of virologic failure. This difference may potentially be explained by other factors not assessed within our model such as education and socioeconomic status, which may be correlated with race. A recent study within our cohort did not find race to be significantly associated with the odds of achieving virologic suppression; however, the prior study also adjusted for educational level, which was found to be significant factor [13].

Index drug was significantly associated with virologic failure and patients on PI- versus NNRTI-based regimens were more likely to be in virologic failure. We did not distinguish patients based on first- or second-line regimen, however, based on the 2008 National HIV/AIDS Program treatment guidelines, NNRTI-based regimens are the preferred first-line regimen and lopinavir/ritonavir is preferred over atazanavir as the second-line PI [15]. Moreover, a prior study demonstrated that of the 1,311 patients initiating ART from January 2000 through June 2010 in our clinical cohort, 75.3% were started on a NNRTI-based regimen [16]. Therefore, one can assume that patients on PI-based regimens were more likely to represent patients who had failed first-line therapy, with poor adherence being one of the possible explanations for prior treatment failure. Differences in tolerability and dosing frequency may also account for the increased risk of virologic failure observed within patients on lopinavir/ritonavir compared to those on atazanavir [17,18]. Further discussion regarding the differences in the associations between index drug and virologic failure is beyond the scope of this report.

The generalizability of our study is limited because we derived the predictive model using only one cohort population. In order to validate further the national use of this predictive model, we would need to replicate our model using other patient databases within the national Brazilian ART pharmacy control system. Perhaps the greatest limitation of our study was the statistical programming required for the derivation of the predictive probability, which limits the ability to apply this tool to day-to-day clinical practice. However, the model could also be used as a surveillance tool by public health authorities to identify the geographic areas with the highest number of patients at risk of virologic failure, in order to implement targeted adherence interventions at the community level. In an effort to simplify the model, we calculated the PDR based solely on the index drug under the assumption that this would be a reliable proxy for overall adherence to therapy. We selected a threshold of >95% for the categorization of the PDR variable based on prior evidence supporting the use of this threshold; however, the median PDR for all intervals was only 0.75. Future research should evaluate lower PDR thresholds to determine if there is an optimal threshold for predicting virologic failure.

### Conclusions

In conclusion, we demonstrated the use of a predictive probability tool based on PDR and index drug for determining the likelihood of virologic failure at a future point in time for varying intervals of assessment. The validation and use of this predictive tool using pharmacy refill data available through the national Brazilian ART pharmacy control system could be of great benefit in early identification of patients with poor adherence and prevent development of treatment failure and drug resistance in Brazil. Following validation of these results, this tool could be applied at the national level in Brazil, and potentially other countries, to identify and further develop targeted adherence interventions in the geographic areas with the highest number of patients at risk of virologic failure. Additionally, further efforts should be made to explore the feasibility of designing a software program within the national Brazilian ART pharmacy control system that would automatize the calculation of the PDR and apply the predictive model on an ongoing basis, such that the system would automatically flag patients at highest risk of clinically significant non-adherence, thereby allowing clinical personnel to proactively intervene with targeted adherence interventions.

### Authors’ affiliations

1Department of Emergency Medicine, Highland Hospital, Oakland, CA, USA; 2Instituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 3Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

### Competing interest

The authors have no competing interests to declare.
**Authors’ contributions**
DM: concept development, statistical analysis, manuscript writing,
PL: concept development, statistical analysis, manuscript draft revision
JJ: concept development, manuscript draft revision
JC: concept development, manuscript draft revision
VV: concept development, data collection, manuscript draft revision
RM: data collection and management, manuscript draft revision
SC: concept development, data collection, manuscript draft revision
JK: concept development, manuscript draft revision
BG: concept development, data collection, manuscript draft revision
All authors have read and approved the final manuscript.

**Acknowledgements**
We would like to acknowledge and thank all of the patients enrolled in the IPEC clinical cohort for their time and contributions to our past, current and future research projects. This work would also not be possible without the hard work and dedication of the staff at IPEC.

**Funding**
Support provided by the National Institutes of Health R25 MH087222 (South American Program in HIV Prevention Research).

**References**
[1] Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
[2] Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006 Oct 15;194 (8):1108–14.
[3] Martin D, Del Cacho E, Codina C, Tuset M, de Lazzari E, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008 Oct;24(10):1263–68.
[4] Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001 Nov 9;15 (16):2109–17.
[5] Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112–18.
[6] Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529–36.
[7] WHO. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva: WHO; 2006.
[8] Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.
[9] Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl.3): S272–8.
[10] McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011 Feb 15;52(4):493–506.
[11] Murphy RA, Sunpath H, Castilla C, Ibrahim S, Court R, Nguyen H, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):158–63.
[12] Court R, Leisegang R, Stewart A, Sunpath H, Murphy R, Winternheimer P, et al. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. BMC Infect Dis. 2014;14:322.
[13] Martin DA, Luz PM, Lake JE, Clark JL, Veloso VG, Moreira RI, et al. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997–2011. BMC Infect Dis. 2014;14:1664.
[14] Aziz TL, Grossberg R, How GR. Long is the right interval for assessing antiretroviral pharmacy refill adherence? J Acquir Immune Defic Syndr. 2010 Aug 15;54(5):e16–8.
[15] Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e Aids. Recomendações para Terapia Anti-retroviral em Adultos Infectados pelo HIV: 2008. 7th ed. Brasília: Ministério da Saúde; 2008.
[16] Cardoso SW, Luz PM, Velasque L, Torres T, Coelho L, Freedberg KA, et al. Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. AIDS Res Ther. 2014 Sep;11(1):29.
[17] Molina JM, Andrade-Villanueva J, Echevarria J, Chethotsiaks P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010 Mar;53(3):323–32.
[18] The HIV-CAUSAL Collaboration. Boosted lopinavir– versus boosted atazanavir–containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis. 2015 Apr 15;60(8):1262–68.